Education
Exploring Semaglutide: Dual Action Therapy for Obesity and Heart Failure
In this episode of Hormone Insights, we delve into a 2024 study from the New England Journal of Medicine that examines the effects of semaglutide in obese patients with heart failure, preserved ejection fraction, and type 2 diabetes.
For full paper, click here
Visit HormoneInsight